MGNX vs ZYME
MGNX: A clinical-stage biotechnology company leveraging proprietary bispecific DART technology and antibody-drug conjugates to develop novel cancer immunotherapies. ZYME: A clinical-stage biotechnology firm building value through a portfolio of novel multifunctional biotherapeutics and strategic royalty assets.
Side-by-side fundamentals
| Metric | MGNX | ZYME | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $3.59 | $28.12 | |
| Market cap | $229M | $2.0B | |
| Net margin FY2025, SEC XBRL | -49.9% | -76.6% | MGNX higher |
| Operating margin FY2025, SEC XBRL | -48.7% | -87.3% | MGNX higher |
| ROE FY2025, SEC XBRL | -134.2% | -30.2% | ZYME higher |
| ROA FY2025, SEC XBRL | -29.1% | -23.4% | ZYME higher |
| Revenue growth (YoY) FY2025, SEC XBRL | -0.3% | +38.9% | ZYME higher |
| Revenue CAGR (3y) SEC XBRL | -0.5% | -36.4% | MGNX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.56 | 0.86 | |
| 1-year return as of 2026-10-21 close | +77.7% | +56.8% | MGNX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.